OCUL Ocular Therapeutix
- 6.290
- +0.240+3.97%
- 6.250
- -0.040-0.64%
Ocular Therapeutix News
Analysts Have Conflicting Sentiments on These Healthcare Companies: Immunocore Holdings (IMCR), Warby Parker (WRBY) and Ocular Therapeutix (OCUL)
Ocular Therapeutix Is Maintained at Buy by HC Wainwright & Co.
Ocular Therapeutix Is Maintained at Buy by HC Wainwright & Co.
Ocular Therapeutix Price Target Cut to $14.00/Share From $16.00 by HC Wainwright & Co.
Ocular Therapeutix Price Target Cut to $14.00/Share From $16.00 by HC Wainwright & Co.
HC Wainwright & Co. : The Ocular Therapeutix (OCUL.US) rating was maintained, adjusted from buy to buy rating, and the target price was adjusted from $16.00 to $14.00.
HC Wainwright & Co. : The Ocular Therapeutix (OCUL.US) rating was maintained, adjusted from buy to buy rating, and the target price was adjusted from $16.00 to $14.00.
HC Wainwright & Co. Maintains Buy on Ocular Therapeutix, Lowers Price Target to $14
HC Wainwright & Co. analyst Yi Chen maintains Ocular Therapeutix with a Buy and lowers the price target from $16 to $14.
Ocular Therapeutix Is Maintained at Market Outperform by JMP Securities
Ocular Therapeutix Is Maintained at Market Outperform by JMP Securities
Ocular Therapeutix Price Target Cut to $22.00/Share From $24.00 by JMP Securities
Ocular Therapeutix Price Target Cut to $22.00/Share From $24.00 by JMP Securities
J.P. Morgan Securities: Maintaining the Ocular Therapeutix (OCUL.US) rating, adjusted from better than market to better than market rating, and adjusted the target price from $24.00 to $22.00.
J.P. Morgan Securities: Maintaining the Ocular Therapeutix (OCUL.US) rating, adjusted from better than market to better than market rating, and adjusted the target price from $24.00 to $22.00.
JMP Securities Maintains Market Outperform on Ocular Therapeutix, Lowers Price Target to $22
JMP Securities analyst Jonathan Wolleben maintains Ocular Therapeutix (NASDAQ:OCUL) with a Market Outperform and lowers the price target from $24 to $22.
Ocular Therapeutix Price Target Cut to $7.00/Share From $11.00 by TD Cowen
Ocular Therapeutix Price Target Cut to $7.00/Share From $11.00 by TD Cowen
Ocular Therapeutix Is Maintained at Hold by TD Cowen
Ocular Therapeutix Is Maintained at Hold by TD Cowen
TD Cowen: Maintaining the Ocular Therapeutix (OCUL.US) rating, adjusted from holding to holding rating, and adjusted target price from $11.00 to $7.00.
TD Cowen: Maintaining the Ocular Therapeutix (OCUL.US) rating, adjusted from holding to holding rating, and adjusted target price from $11.00 to $7.00.
TD Cowen Maintains Hold on Ocular Therapeutix, Lowers Price Target to $7
TD Cowen analyst Tara Bancroft maintains Ocular Therapeutix (NASDAQ:OCUL) with a Hold and lowers the price target from $11 to $7.
Maintaining Buy Rating on Ocular Therapeutix: Financial Growth and Advancements in Clinical Trials Signal Strong Prospects
Ocular Therapeutix Q1 2024 Adj EPS $(0.28) Misses $(0.19) Estimate, Sales $14.774M Miss $15.414M Estimate
Ocular Therapeutix (NASDAQ:OCUL) reported quarterly losses of $(0.28) per share which missed the analyst consensus estimate of $(0.19) by 47.37 percent. The company reported quarterly sales of $14.77
Ocular Therapeutix | 10-Q: Quarterly report
Earnings Flash (OCUL) OCULAR THERAPEUTIX Posts Q1 Revenue $14.8M, Vs. Street Est of $15.4M
04:19 PM EDT, 05/07/2024 (MT Newswires) -- Earnings Flash (OCUL) OCULAR THERAPEUTIX Posts Q1 Revenue $14.8M, vs. Street Est of $15.4M
Ocular Therapeutix 1Q Loss $64.8M >OCUL
Ocular Therapeutix 1Q Loss $64.8M >OCUL
Press Release: Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BEDFORD, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL) ("Ocular"), a biopharmaceutic
Analysts Have Conflicting Sentiments on These Healthcare Companies: Ocular Therapeutix (OCUL) and ModivCare (MODV)
Analysis
Price Target
No Data
